Foghorn Therapeutics
500 Technology Square
Suite 700
Cambridge
Massachusetts
02142
United States
Website: https://foghorntx.com/
Email: info@foghorntx.com
42 articles with Foghorn Therapeutics
-
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
5/9/2022
Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, provided a corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2022.
-
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
-
Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
4/13/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
-
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
4/1/2022
Foghorn ® Therapeutics Inc. today announced the company will have an oral and late-breaking poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.
-
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
3/11/2022
Foghorn® Therapeutics Inc. announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16th, 2022.
-
Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook
3/10/2022
Foghorn Therapeutics Inc. provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021.
-
Flagship will pour in $75 million into Vesalius to support its beginnings, while Rondo raised $67 million to support the development of its preclinical pipeline.
-
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
2/28/2022
Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that Foghorn will participate on a panel at Cowen’s 42nd Annual Health Care Conference which is being held virtually March 7th through March 9th, 2022.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Foghorn Therapeutics Announces Chief Scientific Officer Succession
1/10/2022
Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective, January 10, 2022.
-
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
1/7/2022
Foghorn® Therapeutics Inc. announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022.
-
Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference
11/11/2021
Foghorn Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.
-
Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update
11/9/2021
Foghorn Therapeutics Inc. today provided a corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2021.
-
Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
10/19/2021
Foghorn Therapeutics Inc. today announced that David Millan, PhD, Foghorn’s Vice President of Chemistry, will be presenting at the 4th Annual Targeted Protein Degradation Summit, which is being held virtually October 26-29, 2021.
-
Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
9/1/2021
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.
-
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
8/23/2021
Foghorn Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma.
-
Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
8/10/2021
Foghorn Therapeutics Inc. today provided a corporate update in conjunction with the Company’s From 10-Q filing for the quarter ended June 30, 2021.
-
Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
8/3/2021
Foghorn Therapeutics Inc. today announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, is scheduled to participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference, which is being held from August 10-11.
-
Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
7/9/2021
Foghorn Therapeutics Inc. today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.
-
Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
6/8/2021
Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that it will host a research and development webinar on June 15th from 9:00 AM - 11:00 AM EDT.